UPDATE: Bank of America Lowers Nektar Therapeutics PO, Maintains Underperform

Loading...
Loading...
In a report published Tuesday, Bank of America lowered its Price Objective on Nektar Therapeutics
NKTR
from $7.50 to $7.00, maintaining Underperform rating. Bank of America noted, "following top line ph 3 results for naloxegol in OIC, we have lowered our peak share to 5% (from 10%) in 2020, more than offsetting increased probability of approval. This has lowered our PO for NKTR shares to $7 from $7.50. While there is increased concern that NKTR/AZN may have to assess CV risk in naloxegol (unlikely in our view), we are more concerned about efficacy in the phase 3 studies (KODIAC-04 and -05). In the -05 study, the response rate for the lower dose (12.5mg) was not significant (p=0.202) and the 25mg dose just made the cutoff (p=0.021). Based on the statistical significance levels provided, and a standard deviation estimate derived from THRX and CBST studies, we estimate the PBOadjusted response rate for the 25mg naloxegol dose to be in the 11-16% range, well below the 30% levels achieved by the THRX and CBST drugs (see Chart 1)." Nektar Therapeutics closed at $7.04 on Monday.
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorPrice TargetReiterationAnalyst RatingsBank of America
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...